Rapport Therapeutics (RAPP) said Thursday that preliminary analysis of data from positron emission tomography and the second multiple ascending dose trials for RAP-219 showed it achieved target receptor occupancy within five days of dosing.
The investigational drug also maintained a differentiated tolerability profile, according to the company.
The company is evaluating RAP-219 in patients with refractory focal epilepsy in a phase 2a proof-of-concept trial and expects topline results in mid-2025.
Price: 16.69, Change: -1.10, Percent Change: -6.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。